Stock Analysis
- United States
- /
- Medical Equipment
- /
- NasdaqCM:NURO
NeuroMetrix Third Quarter 2024 Earnings: US$0.75 loss per share (vs US$1.66 loss in 3Q 2023)
NeuroMetrix (NASDAQ:NURO) Third Quarter 2024 Results
Key Financial Results
- Revenue: US$587.3k (down 51% from 3Q 2023).
- Net loss: US$1.51m (loss narrowed by 15% from 3Q 2023).
- US$0.75 loss per share (improved from US$1.66 loss in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
NeuroMetrix shares are down 12% from a week ago.
Risk Analysis
Don't forget that there may still be risks. For instance, we've identified 4 warning signs for NeuroMetrix (3 make us uncomfortable) you should be aware of.
Valuation is complex, but we're here to simplify it.
Discover if NeuroMetrix might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqCM:NURO
NeuroMetrix
A commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China.